Surgical Treatment in Ovarian Cancer - Complete or Optimal Surgery?

Surgical Treatment in Ovarian Cancer - Complete or Optimal Surgery? AbstractSurgical integration in the overall ovarian cancer protocol is conditioned by the performance it has allowed in cytoreduction, the benefits obtained in the interest of the patients in terms of risk (postoperative mortality, severe sequelae, oncology survival criterion at 5 years).Surgical treatment remains the fundamental technical means in the treatment of ovarian cancer. It is performed either in the “first intention” (the strand: High-Probability Clinical Diagnosis, Extemporaneous Histopathological Examination Surgery, Continued Intervention, Postoperative Adjuvant Treatments: Chemotherapy, Radiotherapy, Immunotherapy, Hormone Therapy, Second-look 6 Months), or in “second intent” (precise histopathological / pelviscopic or classic diagnosis, followed by chemotherapy, radiotherapy, immunotherapy and radical surgery). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ARS Medica Tomitana de Gruyter

Surgical Treatment in Ovarian Cancer - Complete or Optimal Surgery?

Loading next page...
 
/lp/degruyter/surgical-treatment-in-ovarian-cancer-complete-or-optimal-surgery-Xls5SiicJb
Publisher
Sciendo
Copyright
© 2018 Niţu Teodor Stefan et al., published by Sciendo
ISSN
1841-4036
eISSN
1841-4036
D.O.I.
10.2478/arsm-2018-0011
Publisher site
See Article on Publisher Site

Abstract

AbstractSurgical integration in the overall ovarian cancer protocol is conditioned by the performance it has allowed in cytoreduction, the benefits obtained in the interest of the patients in terms of risk (postoperative mortality, severe sequelae, oncology survival criterion at 5 years).Surgical treatment remains the fundamental technical means in the treatment of ovarian cancer. It is performed either in the “first intention” (the strand: High-Probability Clinical Diagnosis, Extemporaneous Histopathological Examination Surgery, Continued Intervention, Postoperative Adjuvant Treatments: Chemotherapy, Radiotherapy, Immunotherapy, Hormone Therapy, Second-look 6 Months), or in “second intent” (precise histopathological / pelviscopic or classic diagnosis, followed by chemotherapy, radiotherapy, immunotherapy and radical surgery).

Journal

ARS Medica Tomitanade Gruyter

Published: May 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off